Short Interest in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Decreases By 20.6%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 23,500 shares, a drop of 20.6% from the October 15th total of 29,600 shares. Approximately 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 31,700 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC boosted its holdings in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,570 shares of the company’s stock after acquiring an additional 3,170 shares during the quarter. Aaron Wealth Advisors LLC owned 1.45% of Creative Medical Technology worth $75,000 as of its most recent SEC filing. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ traded up $0.04 during midday trading on Friday, reaching $2.70. 20,410 shares of the stock traded hands, compared to its average volume of 71,907. The company’s 50 day moving average is $3.46 and its 200 day moving average is $3.69. Creative Medical Technology has a one year low of $2.52 and a one year high of $10.28. The stock has a market capitalization of $4.73 million, a PE ratio of -0.71 and a beta of 2.01.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.